Glucose Intolerance, Plasma Insulin Levels, and Colon Adenomas in Japanese Men

Takasei Nishii,1, 4 Suminori Kono,2 Hiroshi Abe,1 Hiroyuki Eguchi,1 Kae Shimazaki,1 Ben Hatano1 and Hiroaki Hamada3

1Self Defense Forces Fukuoka Hospital, 173-2 Kokura, Kasuga-shi, Fukuoka 816-0826, 2Department of Preventive Medicine, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582 and 3Kasukabe Kisen Hospital, 1-53-1 Chuou, Kasukabe-shi, Saitama 344-0067

Hyperinsulinemia may be related to colon carcinogenesis. Several studies have suggested that diabetes mellitus is related to increased risk of colon cancer. We examined cross-sectionally the relation of fasting plasma insulin levels and glucose tolerance status to colon adenomas. In a consecutive series of 951 men undergoing total colonoscopy for a health examination at the Japan Self Defense Forces Fukuoka Hospital from April 1998 to August 1999, we identified 233 cases of colon adenomas and 497 controls with normal colonoscopy. Glucose tolerance status was determined by a 75-g oral glucose tolerance test, and subjects were classified as normal, impaired glucose tolerance (IGT) or non-insulin dependent diabetes mellitus (NIDDM). Plasma insulin levels were measured after subjects had fasted overnight. Logistic regression analysis and analysis of covariance was used to control for age and obesity. While plasma insulin levels were unrelated to colon adenomas, NIDDM was associated with a significantly increased risk of colon adenomas. There was no association between IGT and colon adenomas. NIDDM was more strongly associated with proximal colon adenomas. The findings suggest that long-term hyperinsulinemic status associated with NIDDM may increase the risk of colon adenomas, and subsequently of colon cancer.

Key words: Colon adenomas — Glucose tolerance — Plasma insulin — Japanese men — NIDDM

Hyperinsulinemia or insulin resistance is of interest in connection with colon carcinogenesis.1, 2) Insulin is an important growth factor for colonic mucosa cells,3, 4) and colon cancer tissue has insulin and insulin-like growth factor I receptors.5, 6) Insulin was also shown to promote colon tumor and the growth of colonic aberrant crypt foci in rats.7, 8) Several prospective and case-control studies have observed an increased risk of colon or colorectal cancer associated with diabetes mellitus,4, 10, 11 although such an association has not always been found.12) Further evidence for the role of hyperinsulinemia in colon carcinogenesis is derived from the consistent epidemiological findings that both physical inactivity and obesity are related to increased risk of colon cancer.13, 14) Physical inactivity and obesity are strongly associated with hyperinsulinemia or insulin resistance.15, 16) Few studies have directly addressed the relation between plasma insulin levels and colon cancer. A recent prospective study showed that plasma insulin levels at 2 h after glucose load were significantly positively associated with the risk of colorectal cancer.17

Colorectal adenomas are a well-established precancerous lesion.21) Previously, non-insulin dependent diabetes mellitus (NIDDM) was shown to be associated with a moderately increased risk of sigmoid colon adenomas.22) Several, but not all, studies have also found a positive association of physical inactivity and obesity with colon or colorectal adenomas.23–27) This paper investigated the relation of fasting plasma insulin levels and glucose intolerance as determined by a 75-g oral glucose tolerance test to the prevalence of colon adenomas.

MATERIALS AND METHODS

Subjects Study subjects were men aged 30 years or older who received a voluntary health check-up or a preretirement health examination at the Self Defense Forces (SDF) Fukuoka Hospital from April 1998 to August 1999. In the consecutive series of 1365 men, 951 underwent total colonoscopy. Excluded were those with a prior history of colectomy (n=1), gastrectomy (n=2), or colorectal polyectomy (n=48), those under dietary or drug treatment for diabetes mellitus (n=32), and those whose glucose tolerance status was not determined (n=7); four men had two conditions for exclusion. Of the remaining 866 men, 369 had at least one colorectal polyp, and 497 had normal colonoscopy. Numbers of men by histological diagnosis were: carcinoid 3, adenoma 253, hyperplastic polyp 37, lipoma 2, and inflammatory or normal tissue 74. Cases having rectal adenomas alone (n=20) were excluded. The present analysis included 233 men with colon adenomas as cases and 497 men with normal colonoscopy as
controls. The cases included 14 men having adenomas at the rectum. Numbers of cases with an adenoma of less than 5 mm, 5–9 mm, and 10 mm or greater in diameter were 153, 58, and 22, respectively.

**Health examination** Routine medical examinations were done during a 3-day (voluntary health check-up) or 5-day (preretirement health examination) admission, and included total colonoscopy and a 75-g oral glucose tolerance test. A 75-g oral glucose tolerance test was done after subjects had fasted overnight. Plasma glucose concentration was measured by the glucose oxidase method (Shionotest Co., Ltd., Tokyo). Fasting plasma insulin concentrations were measured by the enzyme immunoassay method at the hospital laboratory using a commercial kit (Dainabot Co., Ltd., Tokyo). Subjects were classified as normal, impaired glucose tolerance (IGT), or NIDDM in accordance with the World Health Organization criteria.28) Body weight and height were recorded, and body mass index (kg/m²) was used as a measure of obesity.

**Statistical analysis** Logistic regression analysis was done to examine the relation of plasma insulin levels and glucose tolerance status to colon adenomas, controlling for age and body mass index. Insulin levels were classified into four categories at the quartiles in the distribution of cases and controls combined. Indicator variables were created to represent the categories of insulin levels and glucose tolerance status. Continuous variables were used for age and body mass index. Crude and adjusted odds ratios (OR) and their 95% confidence intervals (CI) were obtained from logistic regression coefficients and standard errors. Comparison of means was done by unpaired t test, and adjusted means were calculated by analysis of covariance. The distribution of plasma insulin concentrations was skewed to the right side, and natural logarithms of the values were used for the comparison of means. Presented means of plasma insulin levels were always geometric means. Two-sided P values less than 0.05 were regarded as statistically significant. All computations were done by using the Statistical Analysis System software available at Kyushu University Computer Center (SAS Institute, Inc., Cary, NC).

**RESULTS**

Age ranges were 33–58 years in adenoma cases and 30–61 years in the controls; the mean age of adenoma cases (49.3 year) was significantly greater than that of the controls (48.1 year) (P=0.002). Body mass index in the adenoma group did not materially differ from that of the control group (23.8 versus 23.5, P=0.25).

An approximately 2-fold increase was observed in the prevalence odds of colon adenomas associated with NIDDM, but not with IGT, as compared with normal glucose tolerance (Table I). The ORs did not change at all after adjustment for body mass index. The prevalence odds of colon adenoma did not vary according to plasma insulin levels regardless of adjustment for body mass index (Table II).

| Glucose tolerance | No. of cases | No. of controls | Age-adjusted OR (95% CI) | Age- and BMI-adjusted OR (95% CI) |
|-------------------|--------------|-----------------|--------------------------|----------------------------------|
| Normal            | 169          | 386             | 1.0                      | 1.0                              |
| IGT               | 42           | 90              | 1.0 (0.7–1.5)            | 1.0 (0.6–1.5)                    |
| NIDDM             | 22           | 21              | 2.2 (1.2–4.2)            | 2.2 (1.1–4.0)                    |

OR, odds ratio; CI, confidence interval; BMI, body mass index; IGT, impaired glucose tolerance; NIDDM, non-insulin dependent diabetes mellitus.

| Plasma insulin<sub>a</sub> (µU/ml) | No. of cases | No. of controls | Age-adjusted OR (95% CI) | Age- and BMI-adjusted OR (95% CI) |
|-----------------------------------|--------------|-----------------|--------------------------|----------------------------------|
| 0.2–3.0                           | 57           | 129             | 1.0                      | 1.0                              |
| 3.1–4.5                           | 54           | 126             | 1.0 (0.6–1.5)            | 0.9 (0.6–1.5)                    |
| 4.6–6.5                           | 61           | 120             | 1.2 (0.8–1.8)            | 1.1 (0.7–1.7)                    |
| 6.6–35.8                          | 61           | 122             | 1.2 (0.8–1.8)            | 1.1 (0.6–1.7)                    |

OR, odds ratio; CI, confidence interval; BMI, body mass index.

<sup>a</sup> Categorized at quartiles in the distribution of cases and controls combined.
Age-adjusted geometric means of plasma insulin levels were 4.5 (95% CI 4.1–4.8) in adenoma cases and 4.4 (95% CI 4.2–4.6) in the controls. While plasma insulin levels were progressively higher in the IGT and NIDDM groups compared with the group of normal glucose tolerance in both adenoma cases and controls, the means of insulin concentrations were almost equal among adenoma cases and the controls in each stratum of glucose tolerance status (Table III).

When the association with glucose tolerance status was examined for proximal and distal adenomas separately, a more pronounced increase in the OR associated with NIDDM was noted for proximal colon adenomas (Table IV). The prevalence odds of distal adenomas increased only modestly (statistically nonsignificantly), among those with NIDDM. Plasma insulin levels were unrelated to either proximal or distal adenomas, whether or not the size of adenoma was taken into account (data not shown).

**DISCUSSION**

While fasting plasma insulin levels were virtually unrelated to colon adenomas, NIDDM was associated with an increased risk of colon adenomas. The finding adds to evidence that NIDDM is related to increased risk of colon cancer. The lack of a positive association between plasma insulin levels and colon adenomas does not necessarily rule out a role for insulin in colon tumorigenesis. The current levels of plasma insulin may not represent the long-term insulin levels, which are probably more relevant to the development of colon adenomas and cancer. In this regard, the finding that IGT was not associated with colon adenomas is plausible, because those with IGT had probably experienced a shorter duration of hyperinsulinemic status than those with NIDDM. The observed magnitude of an increased risk of adenomas associated with NIDDM is compatible with the risk of colon cancer among those with diabetes mellitus reported elsewhere. Relative risks of 1.3 to 1.4 were reported for colon or colorectal cancer in men with diabetes mellitus in several studies, although the findings in women are less consistent.

A unique finding in the present study is that NIDDM was more strongly associated with proximal colon adenomas than with distal adenomas. We have no plausible explanation for this finding. The site-specific association may be a chance finding due to the subgroup analysis. The 95% CIs for the ORs of distal and proximal adenomas in relation to NIDDM overlapped well. At least two studies have previously addressed the relation of diabetes mellitus to proximal and distal colon cancer separately. In a prospective study in Sweden, a slightly greater relative risk was reported for cancer of the cecum and ascending colon in men and women with diabetes mellitus; the relative risk for cancer of the cecum and ascending colon was 1.55 (95% CI 1.40–1.72) while the relative risks for cancers of the other sites ranged from 1.26 to 1.30. Likewise, in the Nurses’ Health Study, the relative risks associated with diabetes mellitus were 1.64 (95% CI 1.04–2.60) for proximal colon cancer and 1.38 (95% CI 0.88–2.15) for distal colon cancer. In these studies as well, the 95% CIs of the site-specific relative risks overlapped. Further studies are needed to consolidate a stronger association between NIDDM and proximal colon adenomas. The nonsignificant, modest increase in the OR for distal colon adenomas associated with NIDDM was consistent with the finding on sigmoid colon adenomas in the previous study of men retiring from the SDF. In that study, NIDDM was associated with a 1.4-fold increased risk.

### Table III. Age-adjusted Geometric Means of Fasting Plasma Insulin Concentrations (µU/ml) in Colon Adenoma Cases and Controls by Glucose Tolerance Status

| Glucose tolerance | Adenoma cases | Controls |
|-------------------|---------------|----------|
| Normal            | 4.2 (3.8–4.5) | 4.2 (3.9–4.4) |
| IGT               | 5.3 (4.4–6.5) | 5.3 (4.6–6.1) |
| NIDDM             | 5.5 (4.2–7.3) | 5.4 (4.0–7.1) |

Values in parentheses are 95% confidence intervals.

**Table IV. Glucose Tolerance and the Risk of Proximal and Distal Colon Adenomas**

| Site            | Normal | IGT (95% CI)        | NIDDM (95% CI)       |
|-----------------|--------|---------------------|----------------------|
| Proximal adenomas | 83     | 21                  | 14                   |
| OR (95% CI)     | 1.0    | 0.9 (0.5–1.6)       | 2.7 (1.3–5.7)        |
| Distal adenomas | 86     | 21                  | 8                    |
| OR (95% CI)     | 1.0    | 1.0 (0.6–1.8)       | 1.6 (0.7–3.7)        |

IGT, impaired glucose tolerance; NIDDM, non-insulin dependent diabetes mellitus; OR, odds ratio; CI, confidence interval.

a) Adjusted for age and body mass index.
Strengths in the present study are that the study subjects underwent total colonoscopy regardless of glucose tolerance status and that diabetes mellitus was diagnosed on the basis of the standard test. Differential ascertainment or medical surveillance in association with either diabetes mellitus or colon adenomas results in a spurious, positive association between the two disease conditions. There are several weaknesses to be discussed. In the present study, only age and body mass index were taken into consideration. Information was not available regarding other factors such as physical activity, smoking, and alcohol use. Physical inactivity is a known risk factor for NIDDM, and many studies have observed a protective association between physical activity and colon adenomas. A weak, positive association between NIDDM and distal adenomas could be ascribed to physical inactivity. However, if physical inactivity is directly related to both NIDDM and colon adenomas, adjustment for physical inactivity may unmask the true association between NIDDM and colon adenomas. Thus, generalization of the present findings should be done with caution.

Finally, neither adenoma size nor multiplicity of adenomas was taken into account in the present study. Large adenomas (i.e., 10 mm or greater) and multiple adenomas are considered to have a greater potential for malignancy. In the present study, however, cases of such adenomas were very few. Studies on NIDDM and large or multiple colon adenomas would provide more direct evidence regarding the role of glucose intolerance in colon carcinogenesis.

ACKNOWLEDGMENTS

This study was supported in part by a Grant-in-Aid for Scientific Research (B) (12470098) from the Japan Society for the Promotion of Science.

(Received March 12, 2001/Revised May 8, 2001/Accepted May 17, 2001)

REFERENCES

1) McKeown, E. G. Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol. Biomarkers Prev., 3, 687–695 (1994).
2) Giovannucci, E. Insulin and colon cancer. Cancer Causes Control, 6, 164–179 (1995).
3) Watkins, L. F., Lewis, L. R. and Levine, A. E. Characterization of the synergistic effect of insulin and transferrin and the regulation of their receptors on a human colon carcinomacell line. Int. J. Cancer, 45, 372–375 (1990).
4) Koenuma, M., Yamori, T. and Tsuruo, T. Insulin and insulin-like growth factor I stimulate proliferation of metastatic variants of colon carcinoma 26. Jpn. J. Cancer Res., 80, 51–58 (1989).
5) MacDonald, R. S., Thornton, W. H., Jr. and Bean, T. L. Insulin and IGF-1 receptors in a human intestinal adenocarcinoma cell line (Caco-2): regulation of Na+ glucose transport across the brush border. J. Recept. Res., 13, 1093–1113 (1993).
6) Guo, Y. S., Narayan, S., Yallampalli, C. and Singh, P. Characterization of insulin-like growth factor I receptors in human colon cancer. Gastroenterology, 102, 1101–1108 (1992).
7) Tran, T., Medline, A. and Bruce, W. Insulin promotion of colon tumors in rats. Cancer Epidemiol. Biomarkers Prev., 5, 1013–1015 (1996).
8) Corpet, D. E., Jacquinet, C., Peiffer, G. and Tache, S. Insulin injections promote the growth of aberrant crypt foci in the colon of rats. Nutr. Cancer, 27, 316–320 (1997).
9) Ragozzino, M., Melton, L. J., 3rd, Chu, C. P. and Palumbo, P. J. Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. J. Chronic Dis., 35, 13–19 (1982).
10) Steenland, K., Nowlin, S. and Palu, S. Cancer incidence in the National Health and Nutrition Survey I. Follow-up data: diabetes, cholesterol, pulse and physical activity. Cancer Epidemiol. Biomarkers Prev., 4, 807–811 (1995).
11) Wideroff, L., Gridley, G., Mellemkjaer, L., Chow, W. H., Linet, M., Keel, S., Borch-Johnsen, K. and Olsen, J. H. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J. Natl. Cancer Inst., 89, 1360–1365 (1997).
12) Weiderpass, E., Gridley, G., Nyren, O., Ekborn, A., Persson, I. and Adami, H. O. Diabetes mellitus and risk of large bowel cancer. J. Natl. Cancer Inst., 89, 660–661 (1997).
13) Will, J. C., Galuska, A., Vinicor, F. and Calee, E. E. Colorectal cancer: another complication of diabetes mellitus. An. J. Epidemiol., 147, 816–825 (1998).
14) Hu, F. B., Manson, J. E., Liu, S., Hunter, D., Colditz, G. A., Michels, K. B., Speizer, F. E. and Giovannucci, E. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J. Natl. Cancer Inst., 91, 542–547 (1999).
15) O’ Mara, B. A., Byers, T. and Schoenfeld, E. Diabetes mellitus and cancer risk: a multisite case-control study. J.
16) La Vecchia, C., Negri, E., Decarli, A. and Franceschi, S. Diabetes mellitus and colon cancer risk. *Cancer Epidemiol. Biomarkers Prev.*, 6, 1007–1010 (1997).

17) Kune, G. A., Kune, S. and Watson, L. F. Colorectal cancer risk, chronic illness, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. *Cancer Res.*, 48, 4399–4404 (1988).

18) Krisa, A. M. and Bennett, P. H. An epidemiological perspective of the relationship between physical activity and NIDDM: from activity assessment to intervention. *Diabetes Metab. Rev.*, 8, 355–372 (1992).

19) Dowse, G. K., Zimmet, P. Z., Gareeboo, H., George, K., Alberti, M. M., Tuomilehto, J., Finch, C. F., Chitson, P. and Tulsidas, H. Abdominal obesity and physical inactivity as risk factors for NIDDM and impaired glucose tolerance in Indian, Creole, and Chinese Mauritians. *Diabetes Care*, 14, 271–282 (1991).

20) Schoen, R. E., Tangen, C. M., Kuller, L. H., Burke, G. L., Cushman, M., Tracy, R. P., Dobs, A. and Savage, P. J. Increased blood glucose and insulin, body size, and incident colorectal cancer. *J. Natl. Cancer Inst.*, 91, 1147–1154 (1999).

21) O’Brien, M. J., Winawer, S. J., Zauber, A. G., Gottlieb, L. S., Sternberg, S. S., Diaz, B., Dickersin, G. R., Ewing, S., Geller, S. and Kasimian, D. The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. *Gastroenterology*, 98, 371–379 (1990).

22) Kono, S., Honjo, S., Todoroki, I., Nishiwaki, M., Hamada, H., Nishikawa, H., Koga, H., Ogawa, S. and Nakagawa, K. Glucose intolerance and adenomas of the sigmoid colon in Japanese men (Japan). "Cancer Causes Control, 9, 441–446 (1998).

23) Kono, S., Shinchi, K., Ikeda, N., Yanai, F. and Imanishi, K. Physical activity, dietary habits and adenomatous polyps of the sigmoid colon: a study of self-defense officials in Japan. *J. Clin. Epidemiol.*, 44, 1255–1261 (1991).

24) Honjo, S., Kono, S., Shinchi, K., Wakabayashi, K., Todoroki, I., Sakurai, Y., Imanishi, K., Nishikawa, H., Ogawa, S. and Katsurada, M. The relation of smoking, alcohol use and obesity to risk of sigmoid colon and rectal adenomas. *Jpn. J. Cancer Res.*, 86, 1019–1026 (1995).

25) Shinchi, K., Kono, S., Honjo, S., Todoroki, I., Sakurai, Y., Imanishi, K., Nishikawa, H., Ogawa, S., Katsurada, M. and Hirohata, T. Obesity and adenomatous polyps of the sigmoid colon. *Jpn. J. Cancer Res.*, 85, 479–484 (1994).

26) Neugut, A. I., Lee, W. C., Garbowskii, G. C., Waye, J. D., Forde, K. A., Treat, M. R. and Fenoglio, P. C. Obesity and colorectal adenomatous polyps. *J. Natl. Cancer Inst.*, 83, 359–361 (1991).

27) Giovannucci, E., Ascherio, A., Rimm, E. B., Colditz, G. A., Stampfer, M. J. and Willett, W. C. Physical activity, obesity, and risk for colon cancer and adenoma in men. *Ann. Intern. Med.*, 122, 327–334 (1995).

28) World Health Organization Expert Committee on Diabetes Mellitus. World Health Organization Technical Report No. 646 (1980). WHO, Geneva, Switzerland.

29) Baron, J. A., Sandler, R. S., Haile, R. W., Mandel, J. S., Mott, L. A. and Greenberg, E. R. Folate intake, alcohol consumption, cigarette smoking, and risk of colorectal adenomas. *J. Natl. Cancer Inst.*, 90, 57–62 (1998).

30) Sandler, R. S., Lyles, C. M., McCulliffe, C., Woosley, J. T. and Kupper, L. L. Cigarette smoking, alcohol, and the risk of colorectal adenomas. *Gastroenterology*, 104, 1445–1451 (1993).